Brief: CytRx presents updated Aldoxorubicin trial results
06/06/2016 14:00
June 6 (Reuters) - CytRx Corp CYTR.O :
* Cytrx Corp says clinical data presented at asco continues
to support safety and activity of aldoxorubicin in multiple high
unmet need tumor types
* Cytrx presents updated aldoxorubicin clinical trial
results at the 2016 american society of clinical oncology annual
meeting
Source text for Eikon: urn:newsml:reuters.com:*:nPnbR8R8Qa
Further company coverage: CYTR.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C